Ebola Vaccine Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The Ebola vaccine market comprises preventive vaccines targeting multiple ebolavirus species responsible for outbreaks in sub-Saharan Africa. Currently, two vaccines have received WHO prequalification: Merck's Ervebo, which protects against the Zaire ebolavirus strain, and Johnson & Johnson's two-dose Zabdeno/Mvabea regimen. Additional vaccines targeting Sudan ebolavirus and multi-virus formulations are in clinical development.

• •Market valued at approximately $2.3 billion in 2025, with a projected annual growth rate of 7.4%
• •Primary focus on prevention of Zaire, Sudan, and Bundibugyo ebolavirus strains
• •Demand concentrated in endemic regions of sub-Saharan Africa with periodic expansion during outbreak events

Recurring Ebola outbreaks across Central and East Africa have driven sustained demand for vaccines and outbreak preparedness stockpiles. The World Health Organization and Gavi have committed significant resources toward establishing national immunization programs in at-risk countries. Increased emphasis on global health security and lessons learned from the 2014-2016 West Africa epidemic have spurred government and NGO investment.

• •Recent outbreaks, including a current crisis in the Democratic Republic of the Congo and Uganda involving Bundibugyo virus, underscore ongoing need
• •WHO has included Ebola vaccines on its prequalified list, facilitating procurement by national health systems
• •Expansion of ring vaccination strategies and preventive immunization campaigns in high-risk populations

The market is segmented by vaccine type (live-attenuated, viral vector, and other platforms) and end user (governments, NGOs, and healthcare institutions). Geographically, Africa dominates consumption, particularly the Democratic Republic of the Congo, Uganda, Sudan, and Guinea, where outbreaks regularly occur. Secondary markets include the United States, European Union nations, and other countries maintaining national strategic stockpiles.

• •Africa accounts for the largest share of volume demand driven by recurring outbreaks and preventive campaigns
• •North America and Europe represent significant stockpiling and procurement markets for pandemic preparedness
• •Viral vector platforms currently hold the largest market share among vaccine technologies

What are the recent trends and outlook?

The market is moving toward broader strain coverage, with ongoing clinical trials targeting Sudan and Bundibugyo ebolaviruses. Advances in vaccine manufacturing, including thermostable formulations and simplified single-dose regimens, aim to improve accessibility in remote outbreak zones. Partnerships between manufacturers, Gavi, the WHO, and national governments are expected to expand routine vaccination programs in endemic regions.

• •Development of multivalent vaccines covering multiple ebolavirus species is accelerating through clinical trials
• •Investment in next-generation manufacturing technologies and cold-chain-free formulations to improve deployment
• •Growing adoption of preventive vaccination campaigns targeting healthcare workers and at-risk communities in endemic zones